T here is increasing evidence to indicate that patients with rheumatic fever may be genetically programmed to respond abnormally to streptococcal infections. Many investigators have postulated an important role of inherited susceptibility in the causation of rheumatic heart disease. This observation is based on epidemiologic surveys indicating familial occurrence of the disease,1,2 presence or absence of certain blood groups and ABH secretions,3 and association with certain HLA antigens4 of the major histocompatibility complex of humans. Although a simple autosomal recessive pattern of inheritance has been suggested,5 attempts to identify genetic markers of susceptibility in rheumatic heart disease have been only partially successful. We recently reported a significant increase of HLA-DR3 and reduced frequency of HLA-DR2 in a large series of patients with rheumatic heart disease of Asian-Indian origin. 6 Recent studies have rcvealed the existence of a genetically intricate system of serologically defined alloantigens that are selectively expressed on B lymphocytes. With a serum containing B cell alloantibody called 883+, a positive reaction was obtained in approximately 72% of all patients with rheumatic fever from New York and Bogota, Columbia.7 Further, use of two B cell-specific monoclonal antibodies (83s19.23 and 256s10) by the same investigators identified more than 92% of all patients with rheumatic fever. The former antibody (comparable to B cell alloantigen 883+) was positive in at least 59.1% of Indian patients with rheumatic heart disease compared with its reactivity in 16.6% of control subjects. 8 In an effort to further refine the monoclonal genetic markers, these investigators made yet another hybridoma clone, D8/17, the properties of which were different from those of 83s19.23 and 256s10. A preliminary study revealed a 100% positivity of D8/17 in rheumatic patients from New York as compared with 15% in control subjects.9
The present study was undertaken to investigate the prevalence of B cell alloantigen D8/17 and HLA-DR/DQ antigens in patients with rheumatic heart disease of Asian origin and to calculate the frequency of co-occurrence of HLA-DR3 and D8/17 in the patient group as compared with controls. Our results are consistent with the hypothesis that susceptibility to rheumatic heart disease is genetically determined.
Methods

Patients
The present study included 54 patients with established rheumatic heart disease of both sexes admitted to cardiology wards of the All-India Institute of Tables 3 and 4, respectively. An interesting finding was the increasing occurrence of antigen DQw2 of the HLA-DQ locus in patients with rheumatic heart disease (63.4% vs. 31.5%; x2 by Yates', 9.85;p<0.005). This increase in DQw2 was significant only in the D8/17-positive group (Table 5 ). The corrected p value for HLADQw2 in D8/17+ group was statistically significant.
Discussion
An abnormal humoral and cellular immune response to various streptococcal antigens suggests its role in the pathogenesis of rheumatic fever and rheumatic heart disease. Although a strong familial association exists, the mode of inheritance of rheumatic heart disease is unclear. Also, the penetration of this disease is relatively low as evidenced by the lower concordance of rheumatic fever in identical twins15 compared with other infections like poliomyelitis and tuberculosis.16 While a streptococcal etiology of the disease has been proven by several independent lines of inquiry (epidemiologic, serologic, and prophylactic),2'8'9 the low conversion rates of streptococcal pharyngitis into rheumatic fever make the study of host factors, especially genetic susceptibility, relevant.
Because HLA is the most highly polymorphic genetic system thus far known and because human immune response genes exist within this system,17 numerous investigators have sought an association of HLA antigens with rheumatic fever and rheumatic heart disease. An important aspect of the present study concerns the role of HLA class II (DR and DQ) gene products in governing susceptibility to rheumatic heart disease in humans. Numerous investigators have suggested the involvement of HLA-DR antigens in governing susceptibility to rheumatic heart disease, although the exact allele in all these studies is different. [18] [19] [20] This allelic discrepancy in the HLA-DR antigen association in these studies (including ours) can be related to the geographic and racial differences in the genetic background of different populations. In our previous study involving 110 patients, HLA-DR3 appeared significantly increased (p<0.0001) and DR2 significantly reduced (p<0.0001) in patients with rheumatic heart disease of Asian-Indian origin as compared with control subjects.6 In the present study, although DR2 was significantly reduced, HLA-DR3 was only marginally increased (X2 by Yates', 3.2) , despite the fact that the controls in the two studies belong to the same ethnic background. This could be explained on the basis of the smaller number of patients who were available to us for HLA-DR testing. The significant positive association with HLA-DQw2 observed in the present study indicates that the "hypothetic" disease susceptibility gene in rheumatic heart disease may be nearer to the DQ locus than to HLA-DR because HLA-DQw2 is known to be in strong linkage disequilibrium with HLA-DR3. This may be another reason why DR3 did not show a positive association in the present study. This observation assumes significance in view of the recent studies on another autoimmune disease, namely, insulin-dependent diabetes mellitus. Analysis of DNA sequences from diabetics indicates that alleles of HLA-DQB determine both disease susceptibility and resistance and that the structure of the DQ molecule specifies the autoimmune response against the insulin-producing islet cells. 2' Recently, Zabriskie9 proposed that a B cell alloantigen D8/17 could probably be a near-perfect marker for rheumatic fever as it was demonstrated in 100% of their patients with rheumatic heart disease of North American origin. However, this antigen occurred in only 62% of patients with rheumatic heart disease of North Indian origin as evidenced from the results of the present study. The ethnic variability in the expression of D8/17 in different populations does not seem to explain the discrepancy because the frequency of D8/17 in the control Indian population is remarkably similar to that observed in the US caucasians. Nevertheless, the study of D8/17 in patients belonging to other ethnic and racial groups would be important in assessing the value of this marker in rheumatic fever and rheumatic heart disease.
We also tried to investigate whether cooccurrence of D8/17 and DR3/DQw2 produced an "additive effect" on the relative risk over and above that observed when considered separately. Although HLA-DR3 as well as DQw2 were increased in the D8/17-positive samples, the relative risk did not alter significantly when all these markers were considered together. It may be argued that both these antigen systems are independent of each other and that there is no direct relation between them. In this regard, our results support the observations of Zabriskie,8 who conducted screening of B cell alloantisera against a panel of known HLA-ABC and DR specificities and found no association with any of the known HLA phenotypes. The observed increased occurrence of HLA-DQw2 in the D8/17+ patient group as compared with the D8/17 negative group is indeed intriguing. It could be explained on the basis of some degree of structural homology between the two antigen systems. This could be tested by the recently defined molecular hybridization procedures using specific complementary DNA probes for HLA-DR and DQ gene products (and of the D8/17 antigen, if available). The restriction fragment length polymorphisms may prove extremely useful in identifying particular restriction fragments in patients with rheumatic heart disease with or without DQw2 or D8/17.
